Xevant today announced major advances to its VerX™ Platform, unveiling a new set of interconnected systems — Cortex, Pulse, Axis, and Nudge — that together demonstrate the operational reality of RxTech, the emerging technology segment transforming pharmacy benefits to eliminate more than $250 billion in prescription waste and deliver the lowest net cost for medications.

Following VerX’s initial debut earlier this summer, Xevant now shows how its AI-driven platform delivers fully automated cost optimization and member engagement — proving that the RxTech model is no longer conceptual but actively delivering results in real-world pharmacy operations.

“When we launched VerX, we envisioned a platform for the next era of pharmacy benefits,” said Brandon Newman, CEO and Founder of Xevant. “Today, that vision is no longer theoretical. These interconnected systems — Cortex, Pulse, Axis, and Nudge — seamlessly and autonomously operate together to deliver real savings to every stakeholder in pharmacy.”

A Platform of Interconnected Systems

VerX is a platform of intelligent, interconnected systems built to deliver the lowest net cost per claim while improving transparency, performance, and member outcomes across the pharmacy ecosystem.

• Cortex – The AI intelligence center that scans plan, claim, and member data to identify savings opportunities and guide next best actions.
• Pulse – Automates plan operations and performance management, turning static data into real-time intelligence.
• Axis – Connects VerX to internal and market solutions, dynamically routing each claim through the most cost-efficient channel — PBM, manufacturer, or cost-plus.
• Nudge – Uses AgenticAI to engage members directly so savings opportunities become real-world results.

Together, these systems create a closed-loop flywheel of continuous intelligence — ensuring every insight translates into measurable savings and every member action contributes to improved outcomes.

Proof That RxTech Is Here

Recent industry developments — including the TrumpRx–Pfizer agreement enabling direct purchasing at transparent, discounted prices — highlight the accelerating move toward direct distribution and rebate-free economics.

Xevant has already operationalized this shift. Through its VerX Platform, the company delivers solutions that bring the DTP and DTC model to life — including employer-funded GLP-1 carve-outs, Cortex-driven patient assistance that removes out-of-pocket costs, and real-time drug optimization that routes claims to the lowest-cost channel.

Together, these capabilities prove that VerX delivers on the promise of RxTech — not as a concept, but as a functioning system that integrates direct access, intelligent routing, and verified savings into everyday pharmacy management.

“The industry is clearly at an inflection point,” said Nick Conway, President at Value Pharmacy Services. “Legacy models to manage a PBM can’t keep pace with the demand for transparency and real-time optimization. VerX brings the level of intelligence and automation needed to operate in the emerging PBM landscape — it’s a glimpse of where pharmacy infrastructure is headed.”

About Xevant

Xevant is a leader in real-time pharmacy benefits intelligence, helping employers, brokers, and payers gain visibility into true drug costs and unlock measurable savings. Its VerX Platform of Interconnected Systems unites cost containment, optimization, integration, and member engagement into one intelligent flywheel — defining the foundation of the RxTech era. Learn more at www.xevant.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251007419951/en/